Physician profile
Matthew Wells
NPI 1558891812
$3,147.80
in general payments reported to CMS, 2019-2025
30 companies · $874 in 2025
The $874 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.39 · 2021: $528 · 2022: $574 · 2023: $388 · 2024: $761 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.76 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.22 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $470.35 | 2020-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $406.63 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $244.77 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $169.76 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $121.04 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $99.04 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $81.08 | 2021-2025 | Spravato, Xarelto |
| Abbott Laboratories | $80.03 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $74.17 | 2022-2024 | Keveyis, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.22 | 2025 | Jardiance |
| Astellas Pharma US INC | $70.89 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $68.85 | 2024-2025 | |
| Exact Sciences Corporation | $67.84 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $54.47 | 2024 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.32 | 2021-2022 | |
| Corium, LLC | $32.02 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.67 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $30.39 | 2021-2022 | |
| Pfizer INC. | $28.86 | 2022-2023 | |
| Inspire Medical Systems, INC. | $28.47 | 2025 | Inspire |
| Sanofi Pasteur INC. | $26.09 | 2023 | |
| Sumitomo Pharma America, INC. | $25.84 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.03 | 2023 | Trintellix |
| Dexcom, INC. | $21.09 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $20.09 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $19.11 | 2025 | Jornay Pm |
| Bioventus LLC | $16.96 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.26 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $16.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.